The
global Skeletal Dysplasia Market size
is expected to reach USD 3.6 billion by 2026, according to a new report by
Grand View Research, Inc., registering a 4.0% CAGR over the forecast period.
Increasing prevalence of this condition, especially in children, and growing
adoption of orphan drugs are likely to contribute to the expansion of the
market.
Among
different disorders, achondroplasia is the most common condition. According to
estimates published by the National Human Genome Research Institute in 2016,
achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no
current therapies approved specifically for achondroplasia, there are five
therapies under clinical development.
Genetic
defects attributable to the disorder include spontaneous mutations in the FGFR3
gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and
presents a first-in-class drug for achondroplasia. The drug is in phase III
clinical trial and is expected to enter the market in 2024. Clementia (Ipsen
Group) and Regeneron are other market players targeting disorders such as
multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP).
Approval of these pipeline therapies with orphan drug status during the
forecast period will further support skeletal dysplasia market growth.
The
medicines vary depending on the genetic cause of the disorder and only a
handful of the disorders, such as XLH and hypophosphatasia, have approved
curative therapies, including Ultragenyx Pharmaceuticals’ Crysvita and Alexion
Pharmaceuticals’ Strensiq, respectively. Crysvita received FDA approval in 2018
whereas Strensiq received approval in 2015. The sales of Strensiq increased
from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of
these orphan drugs signal growth of the market.
Browse
Details of Report @ https://www.grandviewresearch.com/industry-analysis/skeletal-dysplasia-market
Further key findings from the report suggest:
- Depending on
the disorder, patients develop multiple symptoms ranging from spinal
deformities to abnormal dental development. These disorders limit mobility
and functional abilities in patients
- Commonly
occurring deformities in these disorders include abnormal skeletal
development that require orthopedic procedures and other interventions to
relieve movement obstructions
- Early
identification is crucial for timely medical management. The treatment for
skeletal dysplasia is restricted largely to supportive care
- Surgical
therapy is the most effective treatment option for achondroplasia type
segment of skeletal dysplasia market. There is currently no definitive
treatment for FOP. However, a brief course of high-dose corticosteroids,
such as Prednisone, may help reduce intense inflammation and tissue
swelling seen in early stages.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment